South & Central America Cell and Gene Therapy Market Forecast to 2031 - Regional Analysis - by Type, Services, Scale, Service Providers, and End User

Description

List of Tables

The South & Central America cell and gene therapy market was valued at US$ 67.28 million in 2023 and is projected to reach US$ 184.80 million by 2030; it is estimated to record a CAGR of 13.5% from 2023 to 2031.

Strategic Initiatives by Companies Boost South & Central America Cell and Gene Therapy Market

Many companies involved in manufacturing cell and gene therapy products focus on collaborations, expansions, agreements, partnerships, new product launches, and other strategic developments. These strategic initiatives help them improve sales, expand geographic reach, and enhance capacities to cater to a large customer base. A few of the significant developments in the cell and gene therapy market are as In March 2022, Cellevolve Bio partnered with Seattle Children's Therapeutics to develop and commercialize new multiplex CARs for pediatric cancers. With this collaboration, the companies will focus on the BrainChild research program-a suite of five multiplex CARs-to treat pediatric central nervous system (CNS) malignancies. They aim to leverage the Seattle Children's Cure Factory facility to conduct early clinical GMP research on new CARs. In March 2022, Twist Bioscience Corporation and Kriya Therapeutics, Inc. entered an antibody discovery agreement for antibodies delivered using adeno-associated viral (AAV) gene therapy in therapeutic oncology applications. Also, the companies aim to combine Twist's antibody libraries with Kriya's proprietary vector engineering platform to discover novel antibodies against specific targets of interest to be delivered with Kriya's gene therapy technology. In January 2022, FUJIFILM Corporation agreed to acquire a cell therapy manufacturing facility from Atara Biotherapeutics, Inc. The facility will witness expansion with the flexibility to produce clinical as well as commercial cell therapies, such as allogeneic T-cell and CAR T immunotherapies.

The initiation of new businesses to remain competitive in the market through collaborations and partnerships can help accelerate the development of new platforms for cell and gene therapy manufacturing services. Thus, these strategic initiatives by key players are anticipated to create substantial growth opportunities in the South & Central America cell and gene therapy market during the forecast period.

South & Central America Cell and Gene Therapy Market Overview

Both profit and nonprofit organizations are propelling advanced medical product access and development in Brazil. In March 2024, for example, the Brazilian government's Fundacao Oswaldo Cruz (Fiocruz), a foundation under the Ministry of Health in Brazil, partnered with Caring Cross, a 501(c)(3) nonprofit organization committed to advancing the development of cutting-edge medical treatments and facilitating access to all patients worldwide. Under this partnership, the government aims to establish local production of chimeric antigen receptor (CAR)-T cell and stem cell gene therapies for patients suffering from oncology, infectious, and genetic diseases in Brazil. These therapies also include CAR-T cell therapies for leukemia, lymphoma, and HIV infection. Brazil is attempting a novel collaboration between the Ministry of Health of Brazil and Fiocruz, the public health and research foundation. Therefore, a rise in the initiatives undertaken by profit and nonprofit organizations propel the market growth in the coming years.

South & Central America Cell and Gene Therapy Market Revenue and Forecast to 2031 (US$ Million)

South & Central America Cell and Gene Therapy Market Segmentation

The South & Central America cell and gene therapy market is categorized into type, services, scale, end user, and country.

Based on type, the South & Central America cell and gene therapy market is bifurcated into cell therapy and gene therapy. The cell therapy segment held a larger market share in 2023. Furthermore, the cell therapy segment is sub segmented into allogeneic, autologous, viral vectors. Additionally, the gene therapy segment is divided into non-viral vectors and viral vectors.

In terms of services, the South & Central America cell and gene therapy market is categorized process development, cGMP manufacturing, regulatory services, and bioassay services. The process development segment held the largest market share in 2023.

By scale, the South & Central America cell and gene therapy market is bifurcated into pre-commercial/R&D manufacturing and commercial scale manufacturing. The pre-commercial/R&D manufacturing segment held a larger market share in 2023.

Based on end user, the South & Central America cell and gene therapy market is segmented into contract research, organizations, pharmaceutical and biopharmaceutical companies, and academic and research institutes. The pharmaceutical and biopharmaceutical companies segment held the largest market share in 2023.

By country, the South & Central America cell and gene therapy market is segmented into Brazil, Argentina, and the Rest of South & Central America. Brazil dominated the South & Central America cell and gene therapy market share in 2023.

Catalent Inc, Charles River Laboratories International In, F. Hoffmann-La Roche Ltd, FUJIFILM Holdings Corp, Lonza Group AG, Lotte Corp, Merck KGaA, Takara Bio Inc, and Thermo Fisher Scientific Inc. are some of the leading companies operating in the South & Central America cell and gene therapy market.

Product Code: BMIRE00031474

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macro-economic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country level data:

4. Cell and Gene Therapy Market Landscape

4.1 Overview
4.2 PEST Analysis

5. South & Central America Cell and Gene Therapy Market - Key Market Dynamics

5.1 Cell and Gene Therapy Market - Key Market Dynamics
5.2 Market Drivers
- 5.2.1 Increase in Number of Approval of Cell and Gene Therapies
- 5.2.2 Rapid Popularity of Outsourcing Cell and Gene Therapy Manufacturing
5.3 Market Restraints
- 5.3.1 High Cost of Cell and Gene Therapy Manufacturing
5.4 Market Opportunities
- 5.4.1 Strategic Initiatives by Companies
5.5 Future Trends
- 5.5.1 Automation of Cell and Gene Therapy Manufacturing Services
5.6 Impact of Drivers and Restraints:

6. Cell and Gene Therapy Market -South & Central America Market Analysis

6.1 Cell and Gene Therapy Market Revenue (US$ Million), 2021-2031
6.2 Cell and Gene Therapy Market Forecast Analysis

7. South & Central America Cell and Gene Therapy Market Analysis - by Type

7.1 Cell Therapy
- 7.1.1 Overview
- 7.1.2 Cell Therapy: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
7.2 Gene Therapy
- 7.2.1 Overview
- 7.2.2 Gene Therapy: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)

8. South & Central America Cell and Gene Therapy Market Analysis - by Services

8.1 Process Development
- 8.1.1 Overview
- 8.1.2 Process Development: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
8.2 cGMP Manufacturing
- 8.2.1 Overview
- 8.2.2 cGMP Manufacturing: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
8.3 Regulatory Services
- 8.3.1 Overview
- 8.3.2 Regulatory Services: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
8.4 Bioassay Services
- 8.4.1 Overview
- 8.4.2 Bioassay Services: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)

9. South & Central America Cell and Gene Therapy Market Analysis - by Scale

9.1 Pre-Commercial/R&D Manufacturing
- 9.1.1 Overview
- 9.1.2 Pre-Commercial/R&D Manufacturing: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
9.2 Commercial Scale Manufacturing
- 9.2.1 Overview
- 9.2.2 Commercial Scale Manufacturing: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)

10. South & Central America Cell and Gene Therapy Market Analysis - by Service Providers

10.1 CDMOs
- 10.1.1 Overview
- 10.1.2 CDMOs: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
10.2 CMOs
- 10.2.1 Overview
- 10.2.2 CMOs: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)

11. South & Central America Cell and Gene Therapy Market Analysis - by End User

11.1 Contract Research Organizations
- 11.1.1 Overview
- 11.1.2 Contract Research Organizations: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
11.2 Pharmaceutical and Biopharmaceutical Companies
- 11.2.1 Overview
- 11.2.2 Pharmaceutical and Biopharmaceutical Companies: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
11.3 Academic and Research Institutes
- 11.3.1 Overview
- 11.3.2 Academic and Research Institutes: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)

12. Cell and Gene Therapy Market - Country Analysis

12.1 South and Central America Cell and Gene Therapy Market, by Key Countries - Revenue (2023) (US$ Million)
- 12.1.1 South and Central America: Cell and Gene Therapy Market - Revenue and Forecast Analysis - by Country
  - 12.1.1.1 South and Central America: Cell and Gene Therapy Market - Revenue and Forecast Analysis - by Country
  - 12.1.1.2 Brazil: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
    - 12.1.1.2.1 Brazil: Cell and Gene Therapy Market Breakdown, by Type
      - 12.1.1.2.1.1 Brazil: Cell and Gene Therapy Market Breakdown, by Cell Therapy
      - 12.1.1.2.1.2 Brazil: Cell and Gene Therapy Market Breakdown, by Gene Therapy
    - 12.1.1.2.2 Brazil: Cell and Gene Therapy Market Breakdown, by Services
    - 12.1.1.2.3 Brazil: Cell and Gene Therapy Market Breakdown, by Scale
    - 12.1.1.2.4 Brazil: Cell and Gene Therapy Market Breakdown, by Service Providers
    - 12.1.1.2.5 Brazil: Cell and Gene Therapy Market Breakdown, by End User
  - 12.1.1.3 Argentina: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
    - 12.1.1.3.1 Argentina: Cell and Gene Therapy Market Breakdown, by Type
      - 12.1.1.3.1.1 Argentina: Cell and Gene Therapy Market Breakdown, by Cell Therapy
      - 12.1.1.3.1.2 Argentina: Cell and Gene Therapy Market Breakdown, by Gene Therapy
    - 12.1.1.3.2 Argentina: Cell and Gene Therapy Market Breakdown, by Services
    - 12.1.1.3.3 Argentina: Cell and Gene Therapy Market Breakdown, by Scale
    - 12.1.1.3.4 Argentina: Cell and Gene Therapy Market Breakdown, by Service Providers
    - 12.1.1.3.5 Argentina: Cell and Gene Therapy Market Breakdown, by End User
  - 12.1.1.4 Rest of South and Central America: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
    - 12.1.1.4.1 Rest of South and Central America: Cell and Gene Therapy Market Breakdown, by Type
      - 12.1.1.4.1.1 Rest of South and Central America: Cell and Gene Therapy Market Breakdown, by Cell Therapy
      - 12.1.1.4.1.2 Rest of South and Central America: Cell and Gene Therapy Market Breakdown, by Gene Therapy
    - 12.1.1.4.2 Rest of South and Central America: Cell and Gene Therapy Market Breakdown, by Services
    - 12.1.1.4.3 Rest of South and Central America: Cell and Gene Therapy Market Breakdown, by Scale
    - 12.1.1.4.4 Rest of South and Central America: Cell and Gene Therapy Market Breakdown, by Service Providers
    - 12.1.1.4.5 Rest of South and Central America: Cell and Gene Therapy Market Breakdown, by End User

13. Industry Landscape

13.1 Overview
13.2 Growth Strategies in Cell and Gene Therapy Market
13.3 Organic Growth Strategies
- 13.3.1 Overview
13.4 Inorganic Growth Strategies
- 13.4.1 Overview

14. Company Profiles

14.1 Thermo Fisher Scientific Inc.
- 14.1.1 Key Facts
- 14.1.2 Business Description
- 14.1.3 Products and Services
- 14.1.4 Financial Overview
- 14.1.5 SWOT Analysis
- 14.1.6 Key Developments
14.2 Merck KGaA
- 14.2.1 Key Facts
- 14.2.2 Business Description
- 14.2.3 Products and Services
- 14.2.4 Financial Overview
- 14.2.5 SWOT Analysis
- 14.2.6 Key Developments
14.3 Charles River Laboratories International Inc
- 14.3.1 Key Facts
- 14.3.2 Business Description
- 14.3.3 Products and Services
- 14.3.4 Financial Overview
- 14.3.5 SWOT Analysis
- 14.3.6 Key Developments
14.4 Lonza Group AG
- 14.4.1 Key Facts
- 14.4.2 Business Description
- 14.4.3 Products and Services
- 14.4.4 Financial Overview
- 14.4.5 SWOT Analysis
- 14.4.6 Key Developments
14.5 Takara Bio Inc
- 14.5.1 Key Facts
- 14.5.2 Business Description
- 14.5.3 Products and Services
- 14.5.4 Financial Overview
- 14.5.5 SWOT Analysis
- 14.5.6 Key Developments
14.6 FUJIFILM Holdings Corp
- 14.6.1 Key Facts
- 14.6.2 Business Description
- 14.6.3 Products and Services
- 14.6.4 Financial Overview
- 14.6.5 SWOT Analysis
- 14.6.6 Key Developments
14.7 F. Hoffmann-La Roche Ltd
- 14.7.1 Key Facts
- 14.7.2 Business Description
- 14.7.3 Products and Services
- 14.7.4 Financial Overview
- 14.7.5 SWOT Analysis
- 14.7.6 Key Developments
14.8 Catalent Inc
- 14.8.1 Key Facts
- 14.8.2 Business Description
- 14.8.3 Products and Services
- 14.8.4 Financial Overview
- 14.8.5 SWOT Analysis
- 14.8.6 Key Developments
14.9 Lotte Corp
- 14.9.1 Key Facts
- 14.9.2 Business Description
- 14.9.3 Products and Services
- 14.9.4 Financial Overview
- 14.9.5 SWOT Analysis
- 14.9.6 Key Developments

15. Appendix

15.1 About The Insight Partners
15.2 Glossary of Terms